HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ridker, P. M Search for Related Content PubMed PubMed Citation Articles by Ridker, P. M

High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care

Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave East, Boston, MA 02215, Fax 617 734-1508, E-mail pridker@partners.org

The first 20% of the full text of this article appears below.

Based on more than a decade of evidence, high-sensitivity C-reactive protein (hsCRP)¹ is in clinical use as an inexpensive adjunct to global cardiovascular risk prediction, as a tool to determine risk of future diabetes and metabolic syndrome, and as a method for monitoring efficacy of statin therapy. In the last decade, more than 20 prospective cohort studies have indicated that hsCRP concentrations independently associate with future risk of myocardial infarction, stroke, metabolic syndrome, and type 2 diabetes, and most studies of adequate sample size have found that hsCRP adds prognostic information to global risk prediction scores. On this basis, guidelines for use of hsCRP in clinical practice have been issued by the Centers for Disease Control and Prevention (1), and novel algorithms for risk prediction that incorporate hsCRP, such as the Reynolds Risk Score (www.reynoldsriskscore.com), have been shown to improve risk classification, particularly for "intermediate risk" patients who account for more than 70% of all vascular events (2). Further, as statins lower hsCRP in an LDL cholesterol–independent manner and as best clinical outcomes occur among statin-treated patients who not only reduce LDL cholesterol below 700 mg/L (70 mg/dL) but also reduce hsCRP below 2 mg/L, the concept of "dual goals" has been introduced into cardiovascular clinical practice (3)(4). Because of its relationships with insulin resistance, leptin, and cytokine function (5), as well as its role in endothelial dysfunction and inhibition of fibrinolysis (6)(7), CRP has also been of pathophysiologic interest as an intellectual bridge linking low-grade systemic inflammation to both diabetogenesis . . . [Full Text of this Article]